For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Idera Pharmaceuticals, Inc.

USPTO Granted Patents = 80

% Expired Patents = 65.0

CIPO Patents = 3

EPO Patents = 20

Trademarks = 3

Forward Citations = 1,052

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Sudhir Agrawal (80 out of 153 patents)

Ekambar R Kandimalla (70 out of 78 patents)

Dong Yu (52 out of 66 patents)

4. Daqing Wang (34 out of 34 patents)

5. Lakshmi Bhagat (33 out of 33 patents)

6. Mallikarjuna Putta (12 out of 17 patents)

7. Yukui Li (10 out of 10 patents)

8. Tao Lan (9 out of 9 patents)

9. Qiuyan Zhao (9 out of 15 patents)

10. Ireneusz Nowak (7 out of 7 patents)

11. FuGang Zhu (7 out of 7 patents)

12. Wayne Jiang (5 out of 5 patents)

13. Fu-Gang Zhu (5 out of 5 patents)

14. Rajendra K Pandey (2 out of 6 patents)

15. Jessica Seitzer (1 out of 1 patent)

Core Competencies:

TLR9 Agonists

Immune Regulatory Oligonucleotides

Checkpoint Gene Expression

Stabilized Immune Modulatory RNA

Immunostimulatory Oligonucleotides

Cancer Treatment

Synthetic Agonists

Toll-Like Receptors

Immunomers

Cytokine Induction

Antisense Oligonucleotides

Hypercholesterolemia

80 patents: Sort by Forward Citations

1. 11224611 - Immune modulation with TLR9 agonists for cancer treatment (2022-01-18),

2. 10835550 - Immune modulation with TLR9 agonists for cancer treatment (2020-11-17),

3. 10772907 - Immune modulation with TLR9 agonists for cancer treatment (2020-09-15),

4. 10463686 - Immune modulation with TLR9 agonists for cancer treatment (2019-11-05),

5. 10066230 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2018-09-04),

6. 10041076 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2018-08-07),

7. 9828601 - Compositions for inhibiting checkpoint gene expression and uses thereof (2017-11-28),

8. 9688993 - Toll-like receptor 9 antagonist and methods of use thereof (2017-06-27),

9. 9540651 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2017-01-10),

10. 9453228 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2016-09-27),

11. 9260719 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2016-02-16),

12. 9243050 - Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 (2016-01-26),

13. 9206430 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2015-12-08),

14. 9096858 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response (2015-08-04),

15. 8987221 - Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9 (2015-03-24),

IDERA PHARMACEUTICALS, INC. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel nucleic acid therapeutics for oncology and rare diseases. With a commitment to discover, develop, and deliver innovative therapies, IDERA Pharmaceuticals aims to improve the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Idera Pharmaceuticals, Inc.

80 Patents

#34 in Cambridge, MA

#253 in Massachusetts

#4,621 in US

#9,430 in the World

Cambridge, MA, United States of America

Idera Pharmaceuticals, Inc.

Forward Citations = 1,052

20 inventors:

Sudhir Agrawal (80 out of 153 patents)

Ekambar R Kandimalla (70 out of 78 patents)

Dong Yu (52 out of 66 patents)

4. Daqing Wang (34 out of 34 patents)

5. Lakshmi Bhagat (33 out of 33 patents)

Please report any incorrect information to [email protected]

Loading…